Novartis in Society Integrated Report 2023
Annual Report 2023 and US Securities & Exchange Commission Form 20-F 2023
Other reporting documents
Investor relations
Policies and positions
Positions
Animal research (PDF 0.2 MB) Clinical study transparency (PDF 0.2 MB) Medicines for Patients with Rare Diseases (PDF 0.2 MB) Post-trial Access (PDF 0.1 MB) Pre-Approval Access to Novartis Products through MAPs (PDF 0.3 MB) Responsible Clinical Trials (PDF 0.1 MB) Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB) Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB) Position on Scientific Publications (PDF 0.2 MB)
Codes, Policies and Guidelines
Novartis Third Party Code v. 1.0 (PDF 0.6 MB) * Novartis Third Party Code v. 2.0 (PDF 0.3 MB) ** Novartis Third Party Code v. 3.0 (PDF 0.4 MB) *** Novartis Minimum Information Security Controls for Suppliers (PDF 0.5 MB) Novartis No Purchase Order (PO) No Pay Policy (PDF 0.1 MB)